20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Lexeo Therapeutics, Inc. Common Stock (LXEO) operates in the BIOTECHNOLOGY industry and is headquartered in New York, United States with about 63 employees. Its market capitalization is roughly $258 million. In the fiscal year ended 2025-12-31, LXEO reported $0M in revenue and ($100M) in net income.
Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States.
Interactive charts & full statements →
| Income statement | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $1M | $2M | $1M |
| Gross Profit | — | ($2M) | ($2M) | ($2M) | $1M | $2M | $1M |
| Gross Margin % | — | — | — | — | 100.0% | 100.0% | 100.0% |
| Operating Income (EBIT) | ($95M) | ($109M) | ($106M) | ($69M) | ($61M) | ($51M) | ($5M) |
| Operating Margin % | — | — | — | — | -9252.1% | -3055.9% | -884.9% |
| Net Income | ($87M) | ($100M) | ($98M) | ($66M) | ($59M) | ($51M) | ($5M) |
| Net Margin % | — | — | — | — | -9063.8% | -3055.0% | -993.8% |
| EBITDA | ($85M) | ($98M) | ($96M) | ($64M) | ($58M) | ($51M) | ($5M) |
| Earnings Per Share (EPS) | $-1.16 | $-1.86 | $-3.09 | $-2.49 | $-2.36 | $-2.01 | $-0.20 |
| Shares Outstanding (M) | 86M | 54M | 32M | 27M | 25M | 25M | 25M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M | $0M | $2M | $0M |
| Gross Profit | — | ($1M) | ($1M) | ($1M) | ($1M) | ($1M) | $1M | ($1M) |
| Gross Margin % | — | — | — | — | — | — | 50.0% | — |
| Operating Income (EBIT) | ($28M) | ($22M) | ($23M) | ($22M) | ($31M) | ($34M) | ($27M) | ($32M) |
| Operating Margin % | — | — | — | — | — | — | -1408.5% | — |
| Net Income | ($26M) | ($20M) | ($21M) | ($20M) | ($26M) | ($33M) | ($26M) | ($29M) |
| Net Margin % | — | — | — | — | — | — | -1333.5% | — |
| EBITDA | ($26M) | ($20M) | ($20M) | ($20M) | ($26M) | ($32M) | ($25M) | ($29M) |
| Earnings Per Share (EPS) | $-0.30 | $-0.25 | $-0.27 | $-0.33 | $-0.60 | $-0.99 | $-0.78 | $-0.89 |
| Shares Outstanding (M) | 86M | 81M | 76M | 61M | 44M | 33M | 33M | 33M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($88M) | ($99M) | ($81M) | ($59M) | ($55M) | ($44M) | ($3M) |
| Capital Expenditures (CapEx) | $0M | $0M | $0M | $0M | $1M | $0M | $0M |
| Free Cash Flow (FCF) | ($89M) | ($99M) | ($82M) | ($60M) | ($55M) | ($44M) | ($3M) |
| FCF Margin % | — | — | — | — | -8480.3% | -2677.7% | -604.4% |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($18M) | ($21M) | ($20M) | ($30M) | ($27M) | ($22M) | ($28M) | ($18M) |
| Capital Expenditures (CapEx) | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M |
| Free Cash Flow (FCF) | ($18M) | ($21M) | ($20M) | ($30M) | ($27M) | ($22M) | ($28M) | ($18M) |
| FCF Margin % | — | — | — | — | — | — | -1457.8% | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|---|
| Total Assets | $255M | $269M | $147M | $140M | $97M | $137M | $29M |
| Cash & Cash Equivalents | $93M | $63M | $35M | $121M | $77M | $136M | $29M |
| Total Liabilities | $20M | $22M | $30M | $26M | $210M | $192M | $35M |
| Total Debt (Short + Long-Term) | $3M | $3M | $3M | $3M | $3M | $4M | $1M |
| Total Shareholders' Equity | $235M | $247M | $117M | $114M | ($113M) | ($56M) | ($6M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive LXEO viewer.
About TickerBase · Data methodology & sources · Privacy · Terms